Key result
Melatonin treatment significantly decreased systolic blood pressure in SHR/cp rats with metabolic syndrome compared to untreated controls (159.6 vs 172.5 mm Hg, p<0.05).
Why the study?
Does melatonin reduce blood pressure and alter nitric oxide generation in rats with metabolic syndrome?
Does melatonin reduce blood pressure and alter nitric oxide generation in rats with metabolic syndrome?
Absolute Event Rate: 159.6% vs 172.5%
p-value: p=<0.05
Melatonin reduces blood pressure in a rat model of metabolic syndrome, potentially mediated by increased central nitric oxide production and eNOS upregulation.
No takes yet. Share an insight, caveat, or question.
Melatonin merits human trials in metabolic syndrome hypertension; leaves open nitric oxide pathway translation.
Klimentová et al. (2016) studied Metabolic syndrome and hypertension (n=24). Melatonin vs. Untreated control was evaluated on Systolic blood pressure (p=<0.05). Melatonin treatment significantly decreased systolic blood pressure in SHR/cp rats with metabolic syndrome compared to untreated controls (159.6 vs 172.5 mm Hg, p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: